A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women

NCT04017195 | Completed Phase 1

• 3 other identifiers: CR1086452019-001893-27RWJ10553CON1019
• Study Type: interventional
• Target: 68
• Locations: 3 countries
• Sites: 3

Brief Summary

The main objectives of this study are to determine the bioequivalence of the hormones (example, norelgestromin \[NGMN\] and ethinyl estradiol \[EE\]) from the transdermal contraceptive patch using the newly sourced adhesive component as compared to the currently marketed EVRA patch using the adhesive component, evaluate the adhesion of the transdermal contraceptive patch using the newly sourced adhesive component as compared to the currently marketed EVRA patch using the adhesive component and show non-inferior adhesion of the transdermal contraceptive patch using the newly sourced adhesive component as compared to the currently marketed EVRA patch using the adhesive component.

Conditions

Healthy

Outcome Measures

Primary Outcomes (11)

• Mean Steady-State Concentration (Css) of Norelgestromin (NGMN)

  Css is the mean steady-state concentration for NGMN after patch application, will be calculated, as the mean concentration between 48 hours and 168 hours, inclusive, after patch application.

  48 to 168 hours post-dose

• Mean Steady-State Concentration (Css) of Ethinyl Estradiol (EE)

  Css is the mean steady-state concentration for EE after patch application, will be calculated, as the mean concentration between 48 hours and 168 hours, inclusive, after patch application.

  48 to 168 hours post-dose

• Time to Reach the Maximum Observed Plasma Concentration (Tmax) of NGMN

  Tmax is the time to reach the maximum observed plasma concentration of NGMN will be assessed.

  Predose, 24, 48, 72, 96, 120, 144, 168, 168.5, 171, 174, 180, 192, 216 and 240 hours post dose

• Time to Reach the Maximum Observed Plasma Concentration (Tmax) of EE

  Tmax is the time to reach the maximum observed plasma concentration of EE will be assessed.

  Predose, 24, 48, 72, 96, 120, 144, 168, 168.5, 171, 174, 180, 192, 216 and 240 hours post dose

• Area Under the Plasma Concentration-Time Curve from Time 0 (Patch Application) to Time 168 hours Post-dose (AUC[0-168]) of NGMN

  AUC(0-168) is the area under the concentration versus time curve from zero (patch application) to 168 hours of NGMN in plasma will be assessed.

  Pre-dose to 168 hours post-dose

• Area Under the Plasma Concentration-Time Curve From Time 0 (Patch Application) to Time 168 hours Post-dose (AUC[0-168]) of EE

  AUC(0-168) is the area under the concentration versus time curve from zero (patch application) to 168 hours of EE in plasma will be assessed.

  Pre-dose to 168 hours post-dose

• Area Under the Plasma Concentration-Time Curve From Time 0 (Patch Application) to Time 240 hours Post-dose (AUC[0-240]) of NGMN

  AUC(0-240) is the area under the concentration versus time curve from zero (patch application) to 240 hours of NGMN in plasma will be assessed.

  Pre-dose to 240 hours post-dose

• Area Under the Plasma Concentration-Time Curve From Time 0 (Patch Application) to Time 240 hours Post-dose (AUC[0-240]) of EE

  AUC(0-240) is defined as area under the concentration versus time curve from zero (patch application) to 240 hours of EE in plasma will be assessed.

  Pre-dose to 240 hours post-dose

• Cumulative Adhesion Percentage Ratio

  Adhesion of patches will be assessed in accordance with the European Medicines Agency (EMA) 0-5 scoring system. An estimated percentage of adhesion, to a whole integer, will be obtained (EMA 0-5 \[percentage (%)\] scoring). Estimated percentages of adhesion and corresponding EMA 0-5 score at each interval will be recorded in each participant's electronic case report form. The scoring system for adhesion of transdermal patches is indicated as follows : 0= greater than (\>) 90-100% of the patch area adheres; 1= \>80-90% of the patch area adheres; 2= \>70-80% of the patch area adheres; 3= \>60-70% of the patch area adheres; 4= \>50-60% of the patch area adheres; 5= 0-less than or equal to (\<=) 50% of the patch area adheres.

  Baseline (Day 1) and every 24 hours after patch application up to patch removal at 168 hours (Day 8)]

• Area Under the Plasma Concentration-Time Curve From Time 0 (Patch Application) to Infinite Time (AUC[0-infinity]) for NGMN

  AUC (0-infinity) is the area under the concentration versus time curve from zero (patch application) to infinite time of NGMN in plasma will be assessed.

  Pre-dose to 240 hours post-dose

• Area Under the Plasma Concentration-Time Curve From Time 0 (Patch Application) to Infinite Time (AUC[0-infinity]) for EE

  AUC (0-infinity) is the area under the concentration versus time curve from zero (patch application) to infinite time of EE in plasma will be assessed.

  Pre-dose to 240 hours post-dose

Secondary Outcomes (2)

• Percentage of Participants with Specific Application Site Reactions

  Pre-dose, 168.5, and 192 hours post-dose

• Number of Participants with Adverse Events as a Measure of Safety and Tolerability

  Up to 97 Days

Study Arms (4)

Group 1: Sequence AB (Right/Left)

EXPERIMENTAL

A single patch of currently marketed EVRA patch using the adhesive component at the beginning of shelf life (BOSL) (Treatment A) will be applied to the right buttock of participants on Day 1 of Treatment Period 1, followed by application of a single patch of transdermal contraceptive using newly sourced adhesive component HMW PIB at the end of shelf life (EOSL) (Treatment B) to left buttock of participants on Day 1 of Treatment Period 2. The Treatment periods will be separated by a washout period of 21 days.

Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference); Drug: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)

Group 2: Sequence BA (Right/Left)

EXPERIMENTAL

Treatment B will be applied to the right buttock of participants on Day 1 in Period 1, followed by Treatment A to the left buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.

Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference); Drug: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)

Group 3: Sequence AB (Left/Right)

EXPERIMENTAL

Treatment A will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment B to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.

Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference); Drug: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)

Group 4: Sequence BA (Left/Right)

EXPERIMENTAL

Treatment B will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment A to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.

Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference); Drug: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)

Interventions

EVRA patch (NGMN+EE) (Treatment A) (Reference) DRUG

A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.

Also known as: RWJ10553

Group 1: Sequence AB (Right/Left); Group 2: Sequence BA (Right/Left); Group 3: Sequence AB (Left/Right); Group 4: Sequence BA (Left/Right)

High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test) DRUG

A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.

Group 1: Sequence AB (Right/Left); Group 2: Sequence BA (Right/Left); Group 3: Sequence AB (Left/Right); Group 4: Sequence BA (Left/Right)

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participant has a body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m\^2), inclusive, and body weight not less than 50 kilogram (kg) and not more than 100 kg at screening
• Participant must be surgically sterile with intact ovaries, abstinent, or, if sexually active, be practicing a highly effective method (that is, failure rate of less than \[\<\] 1 percent \[%\] per year) of non hormonal contraception (example, intrauterine device \[IUD\], male partner sterilization) before admission and throughout the study
• Participant has a blood pressure (after the participant is supine or sitting for 5 minutes) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic at screening
• Participant must be a non-smoker, ex-smoker for greater than (\>) 6 months, must not use nicotine containing substances including tobacco products (example, cigarettes, e-cigarettes. cigars, chewing tobacco, gum, patch), or tests negative for cotinine at screening and on Day 1 of each treatment period

You may not qualify if:

• Participant has clinically significant abnormal values for hematology, biochemistry, or urinalysis at screening as deemed appropriate by the investigator
• Participant has abnormal thyroid stimulating hormone level at screening
• Participant has evidence of cervical dysplasia as documented by a CytoRich test or Papanicolaou (PAP) smear test within 10 months before screening. If a PAP smear has been done within 10 months prior to screening and results are available (documentation is available at the study site) a cervical smear does not need to be performed
• Participant has used oral hormonal contraception, that is, contraceptive pills, within 3 months before admission to the study site on Day -1 of Treatment Period 1
• Participant currently has a contraceptive implant such as Implanon or Norplant in place, or has had removal of contraceptive implant within the 3 months before admission to the study site on Day -1 of Treatment Period 1

Sponsors & Collaborators

• Janssen Research & Development, LLC: lead

Study Sites (3)

SGS Belgium NV

Antwerp, 2060, Belgium

Location

Charite - Universitaetsmedizin Berlin (CCM)

Berlin, 10117, Germany

Location

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini

Groningen, 9728 NZ, Netherlands

Location

MeSH Terms

Interventions

Transdermal Patch

Intervention Hierarchy (Ancestors)

Equipment and Supplies

Study Officials

• Janssen Research & Development, LLC Clinical Trial

  Janssen Research & Development, LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 10, 2019
• First Posted: July 12, 2019
• Study Start: July 12, 2019
• Primary Completion: December 13, 2019
• Study Completion: December 13, 2019
• Last Updated: April 27, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will share

Locations

DE (1); NL (1); BE (1)